Properly managing a mare’s hormones is critical for your clients — from the breeding shed to the show ring.

Regu-Mate suppresses estrus in 95 percent of mares after three days of treatment. When treatment is discontinued, mares return to estrus within four to five days.

Trust Regu-Mate to:
- Help alleviate behavior associated with estrus
- Induce cycles in transitional mares for early-season breeding
- Sync estrous cycles for embryo transplant
- Suppress estrus in postpartum mares to help increase fertility
- Efficiently manage semen handling
- Decrease shipping costs
- Reduce number of collections

When everything is at stake, trust Regu-Mate®
Regu-Mate — Tried and tested.

- More than 200 clinical trials conducted to determine safety and efficacy
- More than 30 years of practical use in the field
- More than 20 million doses sold

Regu-Mate® (altrenogest) Solution 0.22% contains the active synthetic progestin, altrenogest. The chemical name is 17α-allyl-17ß-hydroxyestra-4,9,11-trien-3-one. This product is contraindicated for use in mares with a previous stage of pregnancy at doses manyfold greater than the recommended equine dose caused fetal anomalies, specifically infection in some instances.

INDICATIONS:
- To suppress estrus to:
  - 0.22% daily for 15 consecutive days beginning 20 days before the date of the planned estrus. Ovulation will occur 5 days following the onset of estrus, which is expected for nontreated mares. Breeding should follow usual procedures immediately with soap and water.
  - 100%.
  - The oil base may also cause complications if swallowed. In addition, the oil base can disrupt the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, possible pulmonary damage via aspiration of the oil base.
- To facilitate management of the mare exhibiting prolonged estrus during the transition period. Estrus will be suppressed in approximately 95% of the mares within three days; however, continued daily exposure has the potential for more untoward effects such as disruption of the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, possible pulmonary damage via aspiration of the oil base.

ADDITIONAL INFORMATION:
- A 3-year well controlled reproductive safety study was conducted in 27 pregnant mares, 12 to 24 years of age, including 170 singleton mares and 8 triplet mares. The study was conducted at the University of Kentucky and was conducted under the aegis of the National Institutes of Health Animal Welfare Committee. Treatment met the expectations of the regulatory agencies involved.
- Drug metabolism and interaction studies were performed. Regu-Mate, although it must be handled with care, is nonimmunogenic and nonmutagenic as demonstrated by in vivo and in vitro studies.
- Extensive research and development required
- Drug metabolism and interaction studies
- Dose response model to determine safe and hazardous levels
- Mutagenicity and carcinogenicity assessments
- Target animal safety to determine toxicity levels

Only Regu-Mate is Regu-Mate. Don’t leave anything to chance.